Stockscreener 앱 받기
28.82
33.03%
7.025
시간 외 거래:
30.03
1.205
+4.18%
Galecto Inc 주식(GLTO)의 최신 뉴스
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Dividend Watch: Can Galecto Inc lead its sector in growthEarnings Miss & High Conviction Buy Zone Picks - baoquankhu1.vn
Galecto prices $275 million public offering at $19 per share By Investing.com - Investing.com Nigeria
Galecto Prices Upsized Public Offering to Fund DMR-001 - TipRanks
Galecto Signs Underwriting Agreement With Jefferies and Leerink Partners - TradingView
Galecto shares fall after $275 million equity raise at discount By Investing.com - Investing.com South Africa
GLTO: Key Managers Involved in Recent Offering - GuruFocus
Galecto to raise USD 275m in share issue - medwatch.com
Galecto Prices $275 Mln Public Offering At $19 Per Share, Stock Down - Nasdaq
Cancer drug developer Galecto raises $275M in stock sale - Stock Titan
Hans Schambye resigns from Galecto – takes top position at Boost Pharma - medwatch.com
Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - 富途牛牛
Galecto Prices $275 Million Offering - marketscreener.com
Galecto Announces Pricing of $275 Million Underwritten Public Offering - The Manila Times
Galecto, Inc. Announces Pricing of $275 Million Underwritten Public Offering of Common Stock - Quiver Quantitative
Galecto announces pricing of $275 million underwritten public offering - marketscreener.com
Galecto Announces Pricing of $275 Million Underwritten Public Offering - GlobeNewswire Inc.
Galecto announces public offering of common stock and preferred shares By Investing.com - Investing.com Nigeria
Hans Schambye on Galecto exit: It happened by mutual agreement - medwatch.com
Galecto stock falls after announcing public offering of common stock By Investing.com - Investing.com India
Galecto stock falls after announcing public offering of common stock - Investing.com
Galecto (GLTO) Files Automatic Mixed Securities Shelf - GuruFocus
Cancer drug developer Galecto plans stock sale to fund antibody trials - Stock Titan
Galecto CEO Transition and Major Shareholder-Approved Restructuring - TipRanks
Galecto announces CEO transition, share authorization increase, and shareholder approvals - Investing.com India
Galecto (NASDAQ: GLTO) CEO departs amid big share increase and Cayman move - Stock Titan
Returns Recap: How sensitive is Galecto Inc to inflation2025 Market Outlook & High Yield Equity Trading Tips - baoquankhu1.vn
Galecto (NASDAQ:GLTO) Raised to Strong-Buy at Lifesci Capital - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galecto (GLTO), Roche Holding AG (OtherRHHVF) and Amgen (AMGN) - The Globe and Mail
Growth Report: Will Galecto Inc announce a stock splitJuly 2025 Sector Moves & Stepwise Trade Signal Implementation - baoquankhu1.vn
How sensitive is Galecto Inc to inflationTrade Performance Summary & Daily Momentum Trading Reports - baoquankhu1.vn
Galecto Showcases New mutCALR MPN Pipeline at JPM - TipRanks
Risk Report: Is dMY Squared Technology Group Inc Equity Warrant likely to announce a buybackJuly 2025 Update & Entry Point Confirmation Signals - baoquankhu1.vn
Is Galecto Inc a stock for growth or value investorsJuly 2025 EndofMonth & Verified Swing Trading Watchlist - baoquankhu1.vn
Fund Flows: Should I set a stop loss on CNFR2025 Price Targets & Community Consensus Trade Signals - baoquankhu1.vn
Exit Recap: What is Dow Incs book value per sharePortfolio Value Summary & Technical Buy Zone Confirmations - baoquankhu1.vn
Is Galecto Inc. stock supported by innovation pipelineTechnical Breakout Signals & Maximize Gains Professionally - Bollywood Helpline
Galecto, Inc. (NASDAQ:GLTO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Movement Recap: Is Galecto Incs ROIC above industry averageJuly 2025 Setups & Community Verified Watchlist Alerts - baoquankhu1.vn
Galecto (GLTO) Price Target Increased by 13.89% to 41.82 - Nasdaq
Investment Recap: Can Galecto Inc stock double in next 5 yearsEarnings Recap Report & Safe Entry Point Alerts - Bộ Nội Vụ
Galecto on track to submit IND for mutCALR antibody by mid-2026 - Investing.com Nigeria
Galecto on track to submit IND for mutCALR antibody by mid-2026 By Investing.com - Investing.com India
Galecto (GLTO) Sets Ambitious Clinical Milestones for 2026 - GuruFocus
Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones - The Manila Times
Galecto, Inc. Reports Strategic Shift and Financial Results - MSN
Galecto Completes Acquisition of Damora Therapeutics - MSN
Galecto (NASDAQ:GLTO) Upgraded at Leerink Partnrs - Defense World
What risks investors should watch in Galecto Inc. stock2025 Year in Review & Consistent Growth Equity Picks - ulpravda.ru
Is Galecto Inc. stock attractive for hedge fundsJuly 2025 Breakouts & Daily Price Action Insights - Улправда
1.18%
0.13%
자본화:
|
볼륨(24시간):